Adding Ivabradine to Beta-blockers in Chronic Heart Failure: Do Not Rest Without Lowering the Resting Heart Rate Sufficiently

Overview

Journal Indian Heart J

Publisher Elsevier

Specialty Cardiology & Vascular Diseases

Date 2018 May 3

PMID 29716694

Citations 2

Authors

Abraham Oomman

Manish Bansal

Affiliations

Soon will be listed here.

Citing Articles

CAR requires Gadd45β to promote phenobarbital-induced mouse liver tumors in early stage.

Hori T, Yokobori K, Moore R, Negishi M, Sueyoshi T Front Oncol. 2023; 13:1217847.

PMID: 37746289 PMC: 10516603. DOI: 10.3389/fonc.2023.1217847.

Ivabradine: Evidence and current role in cardiovascular diseases and other emerging indications.

Sathyamurthy I, Newale S Indian Heart J. 2019; 70 Suppl 3:S435-S441.

PMID: 30595304 PMC: 6309574. DOI: 10.1016/j.ihj.2018.08.008.

References

Diaz A, Bourassa M, Guertin M, Tardif J . Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J. 2005; 26(10):967-74. DOI: 10.1093/eurheartj/ehi190. View

Farsalinos K, Daraban A, Unlu S, Thomas J, Badano L, Voigt J . Head-to-Head Comparison of Global Longitudinal Strain Measurements among Nine Different Vendors: The EACVI/ASE Inter-Vendor Comparison Study. J Am Soc Echocardiogr. 2015; 28(10):1171-1181, e2. DOI: 10.1016/j.echo.2015.06.011. View

Swedberg K, Komajda M, Bohm M, Borer J, Robertson M, Tavazzi L . Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial).... J Am Coll Cardiol. 2012; 59(22):1938-45. DOI: 10.1016/j.jacc.2012.01.020. View

McAlister F, Wiebe N, Ezekowitz J, Leung A, Armstrong P . Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure. Ann Intern Med. 2009; 150(11):784-94. DOI: 10.7326/0003-4819-150-11-200906020-00006. View

Fox K, Ford I, Steg P, Tendera M, Ferrari R . Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet. 2008; 372(9641):807-16. DOI: 10.1016/S0140-6736(08)61170-8. View

Yancy C, Jessup M, Bozkurt B, Butler J, Casey Jr D, Colvin M . 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society.... J Am Coll Cardiol. 2017; 70(6):776-803. DOI: 10.1016/j.jacc.2017.04.025. View

Colin P, Ghaleh B, Hittinger L, Monnet X, Slama M, Giudicelli J . Differential effects of heart rate reduction and beta-blockade on left ventricular relaxation during exercise. Am J Physiol Heart Circ Physiol. 2002; 282(2):H672-9. DOI: 10.1152/ajpheart.00547.2001. View

Ponikowski P, Voors A, Anker S, Bueno H, Cleland J, Coats A . 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special.... Eur Heart J. 2016; 37(27):2129-2200. DOI: 10.1093/eurheartj/ehw128. View

Tardif J, OMeara E, Komajda M, Bohm M, Borer J, Ford I . Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. Eur Heart J. 2011; 32(20):2507-15. PMC: 3195263. DOI: 10.1093/eurheartj/ehr311. View

10.

Fox K, Ford I, Steg P, Tendera M, Robertson M, Ferrari R . Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet. 2008; 372(9641):817-21. DOI: 10.1016/S0140-6736(08)61171-X. View

11.

Flannery G, Gehrig-Mills R, Billah B, Krum H . Analysis of randomized controlled trials on the effect of magnitude of heart rate reduction on clinical outcomes in patients with systolic chronic heart failure receiving beta-blockers. Am J Cardiol. 2008; 101(6):865-9. DOI: 10.1016/j.amjcard.2007.11.023. View

12.

Swedberg K, Komajda M, Bohm M, Borer J, Ford I, Dubost-Brama A . Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010; 376(9744):875-85. DOI: 10.1016/S0140-6736(10)61198-1. View

13.

Bohm M, Borer J, Ford I, Gonzalez-Juanatey J, Komajda M, Lopez-Sendon J . Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clin Res Cardiol. 2012; 102(1):11-22. DOI: 10.1007/s00392-012-0467-8. View

14.

. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999; 353(9146):9-13. View

15.

Bocchi E, Bohm M, Borer J, Ford I, Komajda M, Swedberg K . Effect of Combining Ivabradine and β-Blockers: Focus on the Use of Carvedilol in the SHIFT Population. Cardiology. 2015; 131(4):218-24. DOI: 10.1159/000380812. View

16.

Kannel W, Kannel C, Paffenbarger Jr R, Cupples L . Heart rate and cardiovascular mortality: the Framingham Study. Am Heart J. 1987; 113(6):1489-94. DOI: 10.1016/0002-8703(87)90666-1. View

17.

Hidalgo F, Anguita M, Castillo J, Rodriguez S, Pardo L, Duran E . Effect of early treatment with ivabradine combined with beta-blockers versus beta-blockers alone in patients hospitalised with heart failure and reduced left ventricular ejection fraction (ETHIC-AHF): A randomised study. Int J Cardiol. 2016; 217:7-11. DOI: 10.1016/j.ijcard.2016.04.136. View

18.

. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999; 353(9169):2001-7. View

19.

Kotecha D, Flather M, Altman D, Holmes J, Rosano G, Wikstrand J . Heart Rate and Rhythm and the Benefit of Beta-Blockers in Patients With Heart Failure. J Am Coll Cardiol. 2017; 69(24):2885-2896. DOI: 10.1016/j.jacc.2017.04.001. View

20.

Wilhelmsen L, Berglund G, Elmfeldt D, Tibblin G, Wedel H, Pennert K . The multifactor primary prevention trial in Göteborg, Sweden. Eur Heart J. 1986; 7(4):279-88. DOI: 10.1093/oxfordjournals.eurheartj.a062065. View